TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is headquartered in Berlin, Germany.…
Total du passif et des capitaux propres de TME Pharma N.V. – HAN:0N6A
TME Pharma (EPA: ALTME) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.1022 EUR on 20 November 2026, up 57.2% over 52 weeks. Its 52-week range is 0.0490 EUR to 0.1746 EUR: the price is 41.5% below the high and 108.6% above the low.
Its market capitalisation is 9.98M EUR.
TME Pharma reports return on equity of 208.0% and revenue up 59.7% year over year.
Its debt exceeds its cash by 1.30M EUR. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.